Business

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

Financial Post · August 18, 2026 at 5:26 p.m.

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built NEW YORK, Aug.

18, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

More from Financial Post

Purpose Investments Inc. Announces August 2026 Distributions

Hampton Financial Corporation Issues Stock Options

News of the day: Economists on tariffs, CRA signing bonus case, shared home ownership, top tech job markets, TMU’s diversity problem and more

JR Wealth Management Launches New Reputation Protection and Strategic Response Service

More in Business

Purpose Investments Inc. Announces August 2026 Distributions

Hampton Financial Corporation Issues Stock Options

News of the day: Economists on tariffs, CRA signing bonus case, shared home ownership, top tech job markets, TMU’s diversity problem and more

JR Wealth Management Launches New Reputation Protection and Strategic Response Service

McFarlane Lake Announces Extension of US$1.69 Million of Remaining Debentures to October 31, 2027

Cerrado Gold Announces Second Quarter 2026 Financial Results